首页|期刊导航|福建师范大学学报(自然科学版)|抗肿瘤纳米药物的器官选择性靶向机制与研究进展

抗肿瘤纳米药物的器官选择性靶向机制与研究进展OA

Organ-selective targeting mechanisms and research advances in antitumor nanomedicines

中文摘要英文摘要

恶性肿瘤仍是威胁人类健康的重大疾病,传统治疗因缺乏选择性常伴随显著毒副作用.纳米载体为药物精准递送提供了新策略,但其体内递送效率低、非特异性富集等问题仍制约临床转化.近年来,器官选择性靶向被认为是突破上述瓶颈的重要方向,可在提高病灶局部药物浓度的同时降低全身毒性.系统总结了纳米药物体内递送的关键生理屏障及其跨越机制,重点梳理了不同器官的结构特征与对应靶向策略,并归纳了近年来器官选择性抗肿瘤纳米药物的代表性研究进展.在此基础上,还对多重屏障协同跨越及人工智能辅助设计等未来发展方向进行了展望,以期为该领域研究与临床转化提供参考.

Malignant tumors remain a major threat to human health,and conventional therapies are often associated with significant toxic side effects due to their lack of selectivity.Nanocarriers provide a promising strategy for precise drug delivery;however,low in vivo delivery efficiency and nonspecific accumulation remain major obstacles to their clinical translation.In recent years,organ-selective targeting has emerged as an important approach to overcoming these bottlenecks,as it can elevate local drug concentrations at lesion sites while reducing systemic toxicity.This review system-atically summarizes the key physiological barriers encountered during in vivo nanomedicine delivery and the mechanisms for overcoming these barriers,with a focus on the structural features of different organs and the corresponding targeting strategies.Representative research advances in organ-selec-tive antitumor nanomedicines in recent years are also outlined.On this basis,future development directions,including the synergistic overcoming of multiple barriers and artificial intelligence-assisted design,are discussed,aiming to provide a reference for research and clinical translation in this field.

雷泽宇;林晨煜;彭海豹

复旦大学脑科学转化研究院,上海 200032||复旦大学基础医学院,上海 200032复旦大学脑科学转化研究院,上海 200032||复旦大学附属中山医院,上海 200032复旦大学脑科学转化研究院,上海 200032

医药卫生

抗肿瘤纳米药物器官选择性靶向递送屏障靶向策略纳米药物设计

antitumor nanomedicinesorgan-selective targetingdelivery barrierstargeting strategiesnanomedicine design

《福建师范大学学报(自然科学版)》 2026 (5)

78-88,11

国家自然科学基金项目(62475047)

10.12046/j.issn.1000-5277.2026050009

评论